Interested in participating? Learn about which studies might be right for you.

NOW ENROLLING NOW ENROLLING
Rare disease patient group icon
STUDY 1| Clinical Interventional

Cyprus2+™ Gene Therapy Phase 1/2/3 Study

Key ELIGIBILITY

18+ icon

Are 18 years of age or older

Wilson Disease icon

Have been diagnosed with Wilson Disease

Liver icon

Are currently on copper chelator and/or zinc therapy

Avocado icon

Limit your intake of high-copper-containing foods

Why are we doing this study?

An investigational gene therapy called UX701 is being tested for the treatment of Wilson Disease. “Investigational” means the study drug is not approved by the US Food and Drug Administration (FDA) and is still being tested in research studies.

Circle with pointer arrow icon

Additional travel support may be available

Ultragenyx recognizes that your participation in clinical research has an impact on your (and your loved ones’) time. We may provide compensation and travel support for participation in our clinical trials—the details may vary program to program. You will learn more during the consent process.

DNA strand

TREATMENT

UX701, an investigational gene therapy

Car icon

SUPPORT

Support is provided for travel costs to clinic visits

Hand reaching for a star icon
Your participation can shape the future of Wilson Disease treatment

What you can expect

IV infusion icon

One-time infusion of study medication into your arm

Lab tests icon

Lab tests (urine, stool, blood, saliva)

Medical records clipboard icon

Medical exams, questionnaires, and interviews

Heart test icon

Heart tests

Human brain icon

Brain imaging

Eye icon

Eye exams

Liver icon

Liver tests

What is involved?

You will enter the study in either Stage 1 or Stage 2, depending on when you enroll.

Stage 1 icon

STAGE 1

UX701
~1 year icon
One intravenous infusion of UX701 followed by oral corticosteroids for ~2 months

STAGE 3A

Follow-up visits only
~4 years icon
11 visits over 4 years (6 can be home-health visits)
Stage 2 icon

STAGE 2

Placebo
~1 year icon
One intravenous infusion of either UX701 or placebo followed by oral
corticosteroids (or placebo) for ~2 months

STAGE 3B

UX701* and follow-up visits
~up to 5 years icon
  • If you received placebo in Stage 2, you will receive UX701 in Stage 3B, if still eligible, followed by ~2 months of oral corticosteroids.</span
  • If you received UX701 in Stage 2, you will receive placebo in Stage 3B, followed by ~2 months of placebo oral corticosteroids.
  • Ongoing clinic and home-health visits to evaluate the long-term safety and efficacy of UX701.

*Dose selected in Stage 1

OR

STAGE 2

UX701*
~1 year icon

One intravenous infusion of either UX701 or placebo followed by oral corticosteroids (or placebo) for ~2 months

*Dose selected in Stage 1

STAGE 3B

Placebo and follow-up visits
~up to 5 years icon
  • If you received placebo in Stage 2, you will receive UX701 in Stage 3B, if still eligible, followed by ~2 months of oral corticosteroids.
  • If you received UX701 in Stage 2, you will receive placebo in Stage 3B, followed by ~2 months of placebo oral corticosteroids.
  • Ongoing clinic and home-health visits to evaluate the long-term safety and efficacy of UX701.

Additional Stage 1 and Stage 2 Information

House icon
3-4 Screening visits (1 can be a home-health visit)
Clinic icon
Once eligible, 2 clinic visits on consecutive days (Baseline visit,
then Dosing Day)
Research collection data icon
After Dosing, 19 follow-up visits over 1 year (14 can be home-health visits)
Interested in participating or have questions? Get started
DNA AND MAGNIFYING GLASS

Understanding Gene Therapy

Gene therapy is the introduction, removal, or change of genetic material in the cells of a person. For certain rare genetic diseases, gene therapy offers the potential for treatment that could have a significant impact on the lives of patients. Find out more details, including how gene therapies are designed to work.

Dig Into the Science

Shield and check mark icon
This study is approved by the Institutional Review Board (IRB), an established organization that protects the rights and welfare of patients participating in research activities.
NOW ENROLLING NOW ENROLLING
Notes icon
STUDY 2| Nonclinical Online Observational

WD Odyssey Study

ELIGIBILITY

Wilson Disease graphic icon

Have been diagnosed (or are the caregiver for someone) with Wilson Disease

United States Map icon

Live in the United States and have received medical care in the US in the past 7 years

A DIFFERENT TYPE OF STUDY

Did you know you and your child’s unique medical history can have a positive impact on the future care for the Wilson Disease community? Anonymized, real-world data from patient medical records can be used to help advance Wilson Disease understanding and potentially improve the quality of care.

Sign up online. It only takes a few minutes.

For more information, see the PicnicHealth study website or connect with a Patient Enrollment Liaison (PEL) team member.

Wilson Disease Odyssey logo
House icon

No TREATMENT or visits

This study allows participants to get their medical records collected, encrypted, and digitized for free—and they’re yours to keep, use, and share as you wish.

Participate in nonclinical research from your home, and help make a difference in Wilson Disease care.

What you need to do

Online signup icon

STEP 1

Sign up: Create a free PicnicHealth account (learn about PicnicHealth below), and sign the consent forms (it only takes a few minutes). Provide the names of your doctors, and we’ll take it from there.

Medical Health Records icon

STEP 2

Wait for your records: Your medical records are collected and digitized into your own PicnicHealth Timeline.

What you can expect

Digitized medical records icon
Access and share your digitized medical records securely
Email icon
Receive information on new research opportunities
Gift card icon
$25 gift card (once eligibility is confirmed)
Test tubes icon
Contribute to Wilson Disease research
Research collection data icon

WHY ARE WE CONDUCTING THIS STUDY?

Wilson Disease research is hard to conduct. By collecting and analyzing anonymized patient data, researchers may gain a greater understanding of Wilson Disease, with the potential to advance future care for patients.

Interested in participating or have questions? Get started

ULTRAGENYX AND PICNICHEALTH

Ultragenyx Pharmaceutical is working in partnership with PicnicHealth, a company that collects, digitizes, and encrypts medical records. If you sign up to participate in this study, you’re agreeing to share your anonymized medical records with researchers and organizations working with PicnicHealth on the study.

Researchers only receive records stripped of any information that could be used to identify you personally. Outside of that, no one outside of PicnicHealth will be able to see your medical record timeline unless you choose to share them.

Interested in taking part in this study?

Get Started

To learn about current and future studies, you only need to fill out the form once.
*All fields are required.

Loading

By submitting this form, you confirm that a diagnosis of Wilson Disease has been made by a medical professional.

If you would like to know more about your privacy and the data you submit and data we collect while you are on this website, please see below or visit our privacy policy.

What happens after you submit your information?

Our Patient Enrollment Liaison (PEL) team will contact you by email or phone within one business day to discuss your study eligibility and answer questions.

If you choose to be contacted by email, be sure to check your spam folder for an email from [email protected], if it’s not in your regular inbox.

Email icon

Got Questions?

Email our PEL team about current and future medical research opportunities.

Wilson Disease patient representation Wilson Disease patient representation

Patient portrayal.

Wilson Disease is a rare genetic disorder caused by an inability to remove excess copper from the body. Too much copper can lead to issues like liver disease and neurological complications.

If you are thinking about joining a study, our Patient Enrollment Liaison (PEL) team is here to help. Every member of our PEL team has a robust professional background and clinical expertise and experience to help answer your questions. Your PEL team member will assist in exploring clinical and nonclinical studies and can determine if you or someone you care for may be eligible to take part. Your PEL is here to make the process as easy as possible.

To speak with a PEL about current and future medical research opportunities, please email our PEL team at [email protected].

When you voluntarily submit your personal data, Ultragenyx stores and processes this information in an electronic database consistent with our Privacy Policy. Ultragenyx will use this information to contact you to fulfill your request regarding Ultragenyx research opportunities.

Clinical and nonclinical studies provide invaluable information to treat, diagnose, or discover new breakthroughs in treating rare and ultra-rare diseases. By choosing to participate in research, you may help advance treatments, provide crucial insights, and ultimately improve the quality of life for others living with a rare or ultra-rare disease. You might also benefit from learning more about your condition, gain access to specific care, or achieve faster access to treatment. All efforts of participation, big and small, can make a difference.

Ultragenyx is leading the future of rare disease medicine. We leverage our experience, insight, and commitment to help move the rare disease community forward. Our primary goal is to provide medicines to those with limited options, and to help patients face rare disease head on with courage and confidence.